Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)

Assessment Status Rapid Review Complete
HTA ID -
Drug Ofatumumab
Brand Arzerra®
Indication In combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Assessment Process
Rapid review commissioned 13/10/2014
Rapid review completed 18/12/2014
Rapid review outcome Full Pharmacoeconomic Assessment Recommended at the submitted price.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.